NPPA suggests expanding the list of essential medicines whose prices are controlled

Sun maintained it would retain the best of both organisations to build a global pharma company.

US country head, key departmental heads leave; more likely to follow.

No Ebola case detected in the country so far; experts say a robust preparedness plan to fight the virus missing.

Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share

Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.

It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues

The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.

Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.

Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.

Altaf Ahmed Lal, country head of the US Food and Drug Administration (US FDA) in India, has quit and so have a few other key officials at the American drug regulator's India office.

Sun-Ranbaxy are keen to complete the merger process.

In a letter to health minister Harsh Vardhan, the Indian Pharmaceutical Alliance, an industry body representing leading pharma companies, including Sun Pharma, Lupin, Dr Reddy's Labs, Cadila Health and Glenmark, stressed the need for an out-of-court settlement with health activists fighting for the rights of clinical trial participants.

The Drug (Prices Control) Order implemented in May last year brought into its purview 652 packs of 348 formulations.

The company did not respond to specific queries on the project's expansion.

Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.

Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.

On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.

ICAI has also imposed a fine of Rs 5 lakh on each of the three accused in Satyam case.

The company buys distressed assets across the globe and turns them around to not only add to its books but also its product pipeline and regions.

The NPPA letter was issued to GSK on Wednesday.

Apart from Wockhardt, only Biocon manufactures insulin analog indigenously.

What started as a mere payment delay seems to have grown into a tussle between the government and leading private hospitals, empanelled under the Central Government Health Scheme.

Legal experts and official sources said the alleged submission of fake documents can also lead to criminal charges against Novartis.

The US Food and Drug Administration has asked USV to probe employees who might have been responsible for inaccurate data reporting.

CCI has accused realty player DLF of preparing one-sided agreement with home buyers

Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.

Swiss drug maker Novartis might face tough action from the country's drug regulator for allegedly giving fake documents while seeking renewal of registration for Tiamulin Hydrogen Fumerate (80 per cent granules), sources said.

Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.

Ranbaxy is facing trouble with its leadership, which has allegedly failed to reach out to its employees working on the ground.

A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.

Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.

Kamal Haasan has filed a complaint with the Competition Commission of India (CCI) against the Tamil Nadu Theatre Owners Association wifor restricting the release of his film Vishwaroopam in theatres last year.

Povidone iodine ointment and solutions are available in the market under various popular brands such as Betadine and Wokadine.

Company claims new use for kala jeera extract, provoking alarmed campaigners here and abroad; says reaction not based on facts.

If the company manages to get a go-ahead from the regulator for this plant, it might result in resumption of supplies of several of their products, barred from the US last year.

Roadblocks ahead as these medicines could face new clinical tests, more scrutiny

The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.

Various domestic companies such as Ranbaxy, Wockhardt and Agila Specialities recently came under the US FDA scanner for lapse in manufacturing practices.

The Drugs Controller General of India is considering the recommendations of its advisory body to revoke the suspension of the sale of analgin-based medicines in the country.